$JNJ
Johnson & Johnson
Diversified healthcare company with pharmaceuticals, medical devices, and consumer products.
JNJ key facts as of November 14, 2026
- Latest AI research report
- JNJ Research: Growth, Valuation and Key Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Strong Buy (5 Strong Buy, 11 Buy, 6 Hold, 1 Sell, 0 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $285.31 mean (range $260.00 to $320.00) (as of November 20, 2026)
- Sector
- Healthcare
Analysis from Nov 13, 2026
JNJ Research: Growth, Valuation and Key Risks
Johnson & Johnson reported a recent earnings beat and its shares are near a 52-week high, while analyst ratings remain broadly positive. But the mean target is close to the Friday close, and valuation and legal risks remain important parts of the picture.
Previous Reports
JNJ FAQ
What is StockAlpha's latest view on JNJ?
StockAlpha's latest AI research report on Johnson & Johnson (JNJ), "JNJ Research: Growth, Valuation and Key Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Johnson & Johnson reported a recent earnings beat and its shares are near a 52-week high, while analyst ratings remain broadly positive. But the mean target is close to the Friday close, and valuation and legal risks remain important parts of the picture.
When was the JNJ research last updated?
The most recent JNJ report was published on November 14, 2026.
What do analysts expect for JNJ?
As of November 1, 2026, the analyst consensus on JNJ is Strong Buy (5 Strong Buy, 11 Buy, 6 Hold, 1 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $285.31 mean (range $260.00 to $320.00).
Is this JNJ research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Johnson & Johnson into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Johnson & Johnson's peers: Today's sector-level news and moves around the stock